GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » Pretax Margin %

AgeX Therapeutics (AgeX Therapeutics) Pretax Margin % : -4,490.91% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. AgeX Therapeutics's Pre-Tax Income for the three months ended in Dec. 2023 was $-3.46 Mil. AgeX Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.08 Mil. Therefore, AgeX Therapeutics's pretax margin for the quarter that ended in Dec. 2023 was -4,490.91%.

The historical rank and industry rank for AgeX Therapeutics's Pretax Margin % or its related term are showing as below:

AGE' s Pretax Margin % Range Over the Past 10 Years
Min: -30947.06   Med: -2880.61   Max: -472.72
Current: -10430.28


AGE's Pretax Margin % is not ranked
in the Biotechnology industry.
Industry Median: -154.03 vs AGE: -10430.28

AgeX Therapeutics Pretax Margin % Historical Data

The historical data trend for AgeX Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AgeX Therapeutics Pretax Margin % Chart

AgeX Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial -708.10 -2,880.61 -5,959.72 -30,947.06 -10,430.28

AgeX Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34,512.50 -32,850.00 -29,766.67 -11,715.22 -4,490.91

Competitive Comparison of AgeX Therapeutics's Pretax Margin %

For the Biotechnology subindustry, AgeX Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AgeX Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where AgeX Therapeutics's Pretax Margin % falls into.



AgeX Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

AgeX Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-14.811/0.142
=-10,430.28 %

AgeX Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-3.458/0.077
=-4,490.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AgeX Therapeutics  (AMEX:AGE) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


AgeX Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AgeX Therapeutics (AgeX Therapeutics) Business Description

Traded in Other Exchanges
Address
1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.
Executives
Jean-christophe Renondin director 505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp. director, 10 percent owner 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett director C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae officer: Chief Financial Officer C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May director 965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West director, officer: Chief Executive Officer AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted officer: Chief Financial Officer 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall officer: Corporate Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg officer: Vice President-Research 935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins director C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin director 3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd 10 percent owner 1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik officer: Chief Operating Officer C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501